Lexeo grants medical chief option on 54,750 shares

The option grant vests over time, subject to continuous service, beginning September 24, 2027.

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. Chief Medical Officer Narinder Pal Bhalla reported acquiring 2,714 common shares on September 14, 2026, under the company’s 2023 Employee Stock Purchase Plan at $3.579 per share. Reported holdings after that transaction were 84,908 shares, including 49,500 restricted stock units. On September 24, 2026, he reported an option grant covering 54,750 common shares, with a $3.39 exercise price and an expiration date of September 23, 2036.

Insider Trade Summary

Grant/Award: 57,464 shares

Grant/Award 2 txns

Insider Bhalla Narinder Pal

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F3	54,750	$0.00	$0.00
Grant/Award	Common Stock F1, F2	2,714	$3.579	$10K

Holdings After Transaction: Stock Option (right to buy) — 54,750 contracts (Direct); Common Stock — 84,908 shares (Direct)

Footnotes (3)

1. F1. The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).
2. F2. Includes 49,500 Restricted Stock Units.
3. F3. 25% of the shares underlying the option vest and become exercisable on September 24, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

Key Figures

Common shares acquired: 2,714 shares Price per share: $3.579 per share Reported holdings after transaction: 84,908 shares +5 more

8 metrics

Common shares acquired 2,714 shares September 14, 2026

Price per share $3.579 per share Acquisition under the 2023 Employee Stock Purchase Plan

Reported holdings after transaction 84,908 shares After the September 14, 2026 transaction; includes 49,500 Restricted Stock Units

Restricted Stock Units 49,500 units Included in reported holdings after the September 14, 2026 transaction

Option grant 54,750 underlying common shares September 24, 2026

Option exercise price $3.39 per share Option covering 54,750 common shares

Initial vesting 25% Vests and becomes exercisable September 24, 2027, subject to continuous service

Option expiration date September 23, 2036 Option covering 54,750 common shares

Key Terms

Employee Stock Purchase Plan, Restricted Stock Units, Rule 16b-3(c), vest and become exercisable

4 terms

Employee Stock Purchase Plan financial

"pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Restricted Stock Units financial

"Includes 49,500 Restricted Stock Units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 16b-3(c) regulatory

"exempt under both Rule 16b-3(c) and Rule 16b-3(d)"

An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.

vest and become exercisable financial

"25% of the shares underlying the option vest and become exercisable"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did LXEO Chief Medical Officer Narinder Pal Bhalla acquire?

Narinder Pal Bhalla reported acquiring 2,714 common shares on September 14, 2026, under Lexeo’s 2023 Employee Stock Purchase Plan at $3.579 per share. His reported holdings after the transaction were 84,908 shares, including 49,500 Restricted Stock Units.

What are the vesting terms for Narinder Pal Bhalla’s LXEO option?

The option covers 54,750 common shares. Twenty-five percent vest and become exercisable on September 24, 2027, and 1/48th of the shares vest in monthly installments thereafter, subject to Bhalla’s continuous service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/28/2026 - 05:15 PM Accepted by SEC EDGAR 09/28/2026 - 05:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bhalla Narinder Pal

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 6TH FLOOR

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/14/2026		A	V	2,714(1)	A	$3.579	84,908(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.39	09/24/2026		A		54,750		(3)	09/23/2036	Common Stock	54,750	$0	54,750	D

Explanation of Responses:

1. The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).

2. Includes 49,500 Restricted Stock Units.

3. 25% of the shares underlying the option vest and become exercisable on September 24, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

	/s/ Youjin Choi, Attorney-in-Fact	09/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)